EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effect of Convalescent Plasma Therapy on COVID-19 Patients: A Retrospective Study

Mahboobeh Shojaei, Saeid Shahrabi, Nastaran Khodakarim, Mehran Amrovani, Alireza Salah, Zohre Saleh Nassaj, Masoud Esmaeili

Jundishapur Journal of Chronic Disease Care · 12.03.2023 · 12 (1)

DOI: 10.5812/jjcdc-133599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Jundishapur Journal of Chronic Disease Care, online erschienen am 12.03.2023. Verfasst von Mahboobeh Shojaei und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Coronavirus disease 2019 (COVID-19) was first detected in December 2019 in Wuhan, China. Different treatments have been used to fight against the virus; however, one of the most effective and accessible is convalescent plasma therapy (CPT).

Objectives

The present study investigated the effect of CPT on improving the clinical conditions of COVID-19 patients.

Methods

This study was conducted on 440 individuals, including 220 COVID-19-recovered individuals as plasma donors and 220 plasma recipients, in Shiraz, Fars province, Iran, from May 2020 to February 2021 using random sampling. After complete recovery from COVID-19, patients were recalled for apheresis and plasma isolation for convalescent plasma (CP) preparation; they were referred to the blood donation centers of Shiraz. According to the hospital request, compatible and related plasma was sent for COVID-19-hospitalized patients. At the same time, hospitals were asked to send the clinical condition documents of the patients based on the medical records and the outcomes after CPT. The Iranian Blood Transfusion Organization evaluated the results.

Results

The median antibody titer was 1300. Titers higher and lower than 1300 were considered high and low, respectively. Blood group O had 54 times higher antibody titers above 1300 than other blood groups (odds ratio (OR) = 54, confidence interval (CI): 19.5 - 205.3, P < 0.001). Additionally, most deceased cases received plasma with antibody titers less than 1300 (OR = 0.08, CI: 0.009 - 0.36, P < 0.001). Nevertheless, most discharged patients received plasma with antibody titers higher than 1300 (OR = 1.5, CI: 1.06 - 2.3, P = 0.01). Moreover, when donors’ antibody titer was higher than 1300, the chance of survival increased by 50%. In addition, the results of this study showed higher mortality in patients whose volume of received plasma was less than 387 mL (OR = 0.3, CI: 0.10 - 0.91, P = 0.018). However, patients who received more than 387 mL CP were more likely to discharge (OR = 5.7, CI: 3.7 - 8.8, P < 0.001).

Conclusions

Using blood group O plasma with a minimum volume of 387 mL can be very effective in improving the clinical symptoms of patients with COVID-19 and increasing the chances of survival for these patients.

Zitieren

APA

Shojaei, M., Shahrabi, S., Khodakarim, N., Amrovani, M., Salah, A., Nassaj, Z. S., & Esmaeili, M. (2023). Effect of Convalescent Plasma Therapy on COVID-19 Patients: A Retrospective Study. Jundishapur Journal of Chronic Disease Care, 12(1). https://doi.org/10.5812/jjcdc-133599

Vancouver

Shojaei M, Shahrabi S, Khodakarim N, Amrovani M, Salah A, Nassaj ZS, et al. Effect of Convalescent Plasma Therapy on COVID-19 Patients: A Retrospective Study. Jundishapur Journal of Chronic Disease Care. 2023;12(1). doi:10.5812/jjcdc-133599

BibTeX
@article{Shojaei2023,
  author = {Shojaei, Mahboobeh and Shahrabi, Saeid and Khodakarim, Nastaran and Amrovani, Mehran and Salah, Alireza and Nassaj, Zohre Saleh and Esmaeili, Masoud},
  title = {Effect of Convalescent Plasma Therapy on COVID-19 Patients: A Retrospective Study},
  journal = {Jundishapur Journal of Chronic Disease Care},
  year = {2023},
  volume = {12},
  number = {1},
  doi = {10.5812/jjcdc-133599}
}
Kostenlos starten →